AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05295784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
Study NCT04815213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: expanded autologous bone marrow derived MSC Laporoscopic
Description: Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
Study NCT04815213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV
Description: Extracellular vesicles injection
Study NCT06174428 — intervention group
Intervention type: DEVICE
Intervention: Oral/Throat cancer test
Description: The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
Study NCT06232018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin adhesive (Dermabond)
Description: * Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied
Study NCT06232018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skin adhesive + polyester mesh (Dermabond prineo)
Description: * Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied
Study NCT05711381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912
Description: Drug: HM15912 Active 0.5mg/kg
Study NCT05827016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days
Study NCT05827016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Specified dose on specified days
Study NCT05744024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality system
Description: The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax \& Distract Application (SyncVR R\&D) will be used.
Study NCT05744024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headphones
Description: Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
Study NCT06089967 — intervention group
Intervention type: OTHER
Intervention: Medical chart review
Description: Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
Study NCT05299242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: 40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
Study NCT05299242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline \[0.9% NaCl\]
Study NCT06101511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs
Description: The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB0123667
Description: 25 mg tablets
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered at protocol defined dose.
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at protocol defined dose.
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered at protocol defined dose.
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at protocol defined dose.
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib will be administered at protocol defined dose.
Study NCT05238922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered at protocol defined dose.
Study NCT06492759 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT06492759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06492759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT06492759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT06492759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT06492759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06492759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06492759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06492759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06492759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06492759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06295692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.
Study NCT06178848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Study NCT06178848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam group
Description: The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Study NCT06484088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frustration task
Description: The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
Study NCT06015893 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take Control
Description: A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.
Study NCT06015893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Control
Description: A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.
Study NCT06015893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).
Study NCT04716569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intranasal ivermectin spray
Description: usage of ivermectin as intranasal spray for treating early covid patiens
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab four 21-day cycles
Study NCT04716569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ivermectin spray
Description: usage of ivermectin as intranasal spray for treating early covid patiens
Study NCT05732454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrasimod
Description: PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
Study NCT05732454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive IV paclitaxel Q3W for four 21-day cycles
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants will receive IV paclitaxel Q3W for four 21-day cycles
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin Q3W for four 21-day cycles
Study NCT05775289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants will receive IV carboplatin Q3W for four 21-day cycles
Study NCT06051227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Study NCT06051227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Study NCT06051227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Study NCT06515990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
Study NCT05076409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Period 1 and period 2
Study NCT05076409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Period 2
Study NCT06104878 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be administered in this study.
Study NCT04945850 — intervention group
Intervention type: PROCEDURE
Intervention: routine care intraocular sx
Description: Fluid was collected during routine intraocular surgery
Study NCT05190354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtremity Polymer Prosthetic Socket
Description: Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
Study NCT06420856 — intervention group
Intervention type: OTHER
Intervention: Assessment of the musculoskeletal system and its functions
Description: Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT
Study NCT06179888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given PO
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Monitoring
Description: Undergo disease monitoring
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skeletal Survey X-Ray
Description: Undergo skeletal survey x-ray
Study NCT06179888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal Survey X-Ray
Description: Undergo skeletal survey x-ray
Study NCT06132893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
Study NCT06132893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
Study NCT05196919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
Study NCT05783310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Intervention
Description: The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
Study NCT05196919 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate-buffered saline for injection
Study NCT04895982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection
Study NCT05055804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELG
Description: The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well.
Study NCT06528704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation feedback device
Description: Device showing delivered ventilation frequency and volume.
Study NCT05554705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle intervention
Description: 12 week therapeutic lifestyle change program
Study NCT05715593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education intervention
Description: health education intervention
Study NCT05526430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harmine Hydrochloride Capsules
Description: capsules taken orally
Study NCT04791748 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular tests
Description: Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
Study NCT06572891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary obturator
Description: conventional acrylic obturator
Study NCT06572891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported obturator
Description: Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made
Study NCT05680480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Description: Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
Study NCT05680480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Description: Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
Study NCT05680480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo weekly in addition to SOC for 48 weeks.
Study NCT06090864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.